AstraZeneca and Sanofi have secured approval in the ... It is the first approval for Beyfortus (nirsevimab) by any regulatory authority. AZ's Synagis (palivizumab) is currently the only approved ...

Along with Beyfortus (nirsevimab), it is also a potential rival ... held back by manufacturing capacity constraints, and AZ and Sanofi are predicting it will cross the $1 billion threshold this ...

Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

They also may have implications for when the RSV monoclonal antibody, Nirsevimab, should be administered to newborns. Similar research should be conducted for other vaccines administered during ...

the American Academy of Pediatrics recommends that certain high-risk young children between 8 and 19 months of age also receive a dose of nirsevimab or palivizumab to protect them during their ...

Some states had their own RSV programs this year – in NSW, Beyfortus was available for vulnerable babies – but Butler said the new program would cater to all mothers and babies in Australia.

Aug 17, 2024 18:48 Sanofi Gets CDSCO Nod for Beyfortus in India - Prevention of RSV Sanofi India receives marketing authorization for Beyfortus, a treatment for preventing Respiratory Syncytial Virus ...

Respiratory syncytial virus (RSV) is the most important cause of infantile bronchiolitis and pneumonia. It is ubiquitous, with most children acquiring their primary infection within the first year ...